UNSPSC 51282001: Dactinomycin

This classification denotes an actinomycin antibiotic with the molecular formula C62H86N12O16, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 1CC1JFE158, chemically known as 4,6-dimethyl-3-oxo-3h-phenoxazine-1,9-dicarboxamide but generally known as dactinomycin, which bears US NIH Compound Identifier 2019. European Medicines Agency schedules Dactinomycin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB13528MIG.

UNSPSC 51282001 Dactinomycin is a Commodity code covering generic and proprietary pharmaceuticals supplied through state and local procurement channels, with recent activity reflecting demand for multi-source generic drugs and over-the-counter products distributed across participating government facilities. State and local procurement under this code centers on establishing supply contracts with pharmaceutical manufacturers who can meet cGMP certification, Drug Supply Chain Security Act compliance, and specific pricing and product-data requirements. Issuing bodies include state departments of administration and multistate cooperative purchasing alliances that aggregate demand across member states, counties, municipalities, and other local government facilities. The cooperative purchasing model dominates current activity, with multiple authorized wholesalers (typically three or four) serving as fulfillment channels to end-user agencies.

The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, issued an RFP in January 2026 (S1070000015802) to establish multiple contracts for generic multi-source pharmaceuticals and OTC products with a March 26, 2026 proposal deadline and July 1, 2026 contract effective date. The solicitation targets manufacturers capable of supplying through AmerisourceBergen Drug Corporation (Cencora), Cardinal Health, and Morris & Dickson Co., LLC, with pricing weighted at 75 percent of evaluation and compliance with administrative data formats and electronic data interchange capability each weighted at 5 percent. Vendors must maintain $5,000,000 commercial general liability coverage, $2,000,000 network security and privacy liability coverage, and $2,000,000 professional liability coverage, and agree to a 3 percent administrative fee on all purchases. The contract term runs two years for new vendors with optional extensions, while incumbent responders' amendments extend through June 30, 2028. MMCAP reserves discretion to award sole, dual, or multiple vendors based on therapeutic considerations and member-specific needs, with no specific set-aside designations disclosed in available documentation.